Tizadin (Tizanidine Hydrochloride)|Centrally Acting Skeletal Muscle Relaxant
Overdose
Symptoms: Somnolence, dizziness, nausea, vomiting, miosis, hypotension, QT prolongation, bradycardia, coma, respiratory depression.
Management: Activated charcoal (repeated doses), forced diuresis. Supportive/symptomatic treatment.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Tizadin is indicated for:
Painful muscle spasms associated with:
Class: Centrally acting skeletal muscle relaxant
Mechanism of Action:
Acts at the spinal cord level by stimulating presynaptic alpha-2 adrenergic receptors.
Inhibits the release of excitatory amino acids that activate NMDA receptors.
Suppresses polysynaptic transmission in spinal interneurons → reduces excessive muscle tone.
Effects:
Relieves spasms, clonus, and resistance to passive movements.
May improve voluntary strength.
Exerts mild central analgesic activity.
Pharmacodynamics: Efficacy and side effects correlate with plasma concentration levels.
Pregnancy: Limited human data; use only if the benefit > risk. Animal studies show fetal harm at high doses.
Lactation: Avoid—no human data; excreted in animal milk.
Elderly: Increased sensitivity; titrate carefully.
Children (<18 yrs): Not recommended.
Very Common: Somnolence, dizziness, fatigue, dry mouth, GI disturbances, muscular weakness.
Common: Nausea, hypotension, insomnia, abnormal liver enzymes.
Uncommon: Bradycardia.
Rare/Severe: Hallucinations, hepatitis, hypersensitivity (rash, angioedema, anaphylaxis).
⚠️ Tizanidine has a narrow therapeutic index → dosing must be individualized.
Painful muscle spasms (acute):
Spasticity (neurological origin):
Elderly (≥65 yrs): Start at the lowest dose; increase cautiously.
Renal impairment (<25 mL/min): Start 2 mg once daily; titrate slowly.
Hepatic impairment: Contraindicated in severe cases; use cautiously with moderate impairment.
Pediatrics (<18 yrs): Not recommended.
Discontinuation: Taper gradually to avoid rebound hypertension and tachycardia.
Hypersensitivity to tizanidine.
Severe hepatic impairment.
Concomitant use with strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin).
Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin): Contraindicated → massive increase in plasma levels, risk of hypotension, QT prolongation.
Other CYP1A2 inhibitors (amiodarone, cimetidine, fluoroquinolones, oral contraceptives, ticlopidine, rofecoxib): Not recommended.
Rifampicin: ↓ plasma levels by ~50% → may reduce efficacy. Avoid long-term use.
Cigarette smoking (>10/day): ↓ exposure by ~30% → may require higher doses.
Alcohol: Increases CNS depression, hypotension, sedation → avoid.
Other CNS depressants (benzodiazepines, baclofen, antihistamines, sedatives): Potentiation of sedation.
Antihypertensives: Risk of hypotension, bradycardia, rebound hypertension on withdrawal.
QT-prolonging drugs (cisapride, amitriptyline, azithromycin): Use with caution.
Hypotension risk → monitor BP, especially with antihypertensives or CYP1A2 inhibitors.
Hepatic monitoring → check LFTs monthly for first 4 months if ≥12 mg/day. Discontinue if SGPT/SGOT >3× ULN.
Renal impairment: Start at low dose (2 mg daily).
Withdrawal syndrome: Taper dose slowly to prevent rebound hypertension/tachycardia → risk of stroke.
Driving/Operating machinery: May cause drowsiness, dizziness, and sedation.
Hypersensitivity reactions (including anaphylaxis) may occur; discontinue immediately if symptoms appear.
Store below 30°C, in a dry place, protected from light.
Keep out of reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.